

AMENDMENTS TO THE SPECIFICATION

At page 10, please replace paragraphs 2-4 with the following replacement paragraphs:

There are no particular limitations to metronidazole, and, for example, “~~Asuzole~~ ACUZOLE tablet 250 mg (trade name)” (Fuji Pharmaceutical Co. Ltd) may be used.

There are no particular limitations to minocycline, and, for example, “~~Minomycine~~ MINOMYCIN 100 mg (trade name)” (Weis Inc.) may be used.

There are no particular limitations to ciprofloxacin, and, for example, “~~Cyproxane~~ CYPROXANE 200 mg (trade name)” (Bayer AG) may be used.

At page 11, please replace paragraph 3 with the following replacement paragraph:

In addition, there are no particular limitations to polyethylene glycol, and, for example, “~~Solbase~~ SOLBASE (brand name; a 1:1 mixture of PEG-400 and PEG-4000)” (Dainippon Pharmaceutical Co.) may be used.

Please replace the paragraph bridging pages 19 and 20 with the following replacement paragraph:

The covering process is a process of covering the opening of a tooth administered with the treatment composition. By covering the opening, the invasion of oral bacteria into the sterilized site is blocked so as to maintain sterile conditions. Specifically, the tooth opening is covered with a filling material (e.g., glass-ionomer cement “~~Fuji-IX-GP~~ FUJI IX GPTM (brand name)” (G C Co., Ltd.) so as to cover the administered treatment composition.

At page 20, please replace the first paragraph with the following replacement paragraph:

In addition, in the case of root canal treatment, after the above-described treatment composition is applied to its administering seat, it may be covered with hydraulic cement (e.g. “Caviton CAVITON[®] (~~registered trade mark~~)” (G C Co., Ltd.)) which may be further covered with phosphate cement.

At page 23, please replace the fifth paragraph with the following replacement paragraph:

With the treatment method according to the above-described embodiment, formation of the treatment drug layer 13A over the administering site 15 alone enables the diffusion of the treatment composition through dentinal canals and gaps between root canal and root-filling material to the alveolar bone, and the ~~time~~ like, thereby achieving the sterilization of bacterial invasion sites such as alveolar bone, and the like.

At page 24, please replace the third paragraph with the following replacement paragraph:

First, the mandibular first premolar affected with apical periodontitis was drilled with a #70 reamer to enlarge the root canal and further the root canal was filled using a gutta-percha point and a sealer, and by pressing them sideways. Subsequently a nearly cylindrical hole about 2 mm deep from the cervical line and about 1.5 mm in diameter was formed. (hereinafter this hole is referred to as the drug application seat 52 of the above-described administering site). At the bottom of this drug application seat 52, two small pieces 53 (about 1.0 mm in diameter) of each base shown in Table 1 added with food red were loaded. Furthermore, cotton ball (not shown) was placed so as to cover these small pieces 53, and “Caviton CAVITON[®] (~~registered trade mark~~)” (G C Co., Ltd.) was layered over this cotton ball to form the covering layer 54, thereby preparing the sample 50.

At page 25, please replace Table 1 with the following replacement Table 1:

Table 1

| Sample No. | Composition |
|------------|--|
| 1 | Water |
| 2 | Propylene glycol |
| 3 | "Solbase <u>SOLBASE</u> (brand name)":propylene glycol = 1:1 (mass ratio) |
| 4 | Polyethylene glycol 4000:propylene glycol = 3:1 (mass ratio) |
| 5 | Polyethylene glycol 600 |
| 6 | Glycerin |